OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

Introduction. Imatinib mesylate (IM) remains a treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and providing a perspective for a long disease-free survival. Due to the long-term administration of IM, the questions about the possible impact on the development of s...

Full description

Bibliographic Details
Main Authors: Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien
Format: Article
Language:English
Published: PAGEPress Publications 2015-01-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
chronic myeloid leukemia, imatinib mesylate, tyrosine kinase inhibitors, secondary malignancies
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/2045

Internet

http://www.mjhid.org/index.php/mjhid/article/view/2045

Similar Items